The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics
- PMID: 25216521
- PMCID: PMC4196181
- DOI: 10.18632/oncotarget.2053
The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics
Abstract
Cancer stem cells (CSC) are believed to be involved in tumor evasion of classical antitumor therapies and have thus become an attractive target for further improvement of anticancer strategies. However, the existence and identity of CSC are still a matter of controversy. In a systematic screen of 13 ovarian cancer cell lines we show that cells with stem cell properties are reliably detectable as a minor population, characterized by ABC transporter expression resulting in the side population (SP) phenotype. In different cell lines, either ABCG2 or ABCB1 was found to be responsible for this effect. Purified SP cells featured virtually all characteristics of bona fide CSC, including clonogenicity, asymmetric division and high tumorigenicity in vivo. Using in-depth phenotyping by multicolor flow cytometry, we found that among the investigated ovarian cancer cell lines the SP compartment exhibits tremendous heterogeneity and is composed of multiple phenotypically distinct subpopulations. Thus, our study confirms previous results showing that CSC are contained within the SP. However, the exact identity of the CSC is still disguised by the high complexity of the CSC-containing compartment. Further functional studies are needed to determine whether a single cellular subset can unambiguously be defined as CSC or whether multiple stem cell-like cells with different properties coexist. Moreover, the observed heterogeneity may reflect a high level of plasticity and likely influences tumor progression, escape from immune-surveillance and development of resistance to anticancer therapies and should therefore be considered in the development of new treatment strategies.
Conflict of interest statement
The authors declare that there is no conflict of interest. There is also no non-author involvement in the preparation of the manuscript.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4196181/bin/oncotarget-05-7027-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4196181/bin/oncotarget-05-7027-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4196181/bin/oncotarget-05-7027-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4196181/bin/oncotarget-05-7027-g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4196181/bin/oncotarget-05-7027-g005.gif)
Similar articles
-
Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.Stem Cells. 2011 Mar;29(3):452-61. doi: 10.1002/stem.582. Stem Cells. 2011. PMID: 21425408
-
MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells.Int J Clin Exp Pathol. 2014 May 15;7(6):2934-41. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25031712 Free PMC article.
-
PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.Cancer Lett. 2016 Jun 28;376(1):148-54. doi: 10.1016/j.canlet.2016.03.041. Epub 2016 Mar 29. Cancer Lett. 2016. PMID: 27037060
-
Side population cells as prototype of chemoresistant, tumor-initiating cells.Biomed Res Int. 2013;2013:517237. doi: 10.1155/2013/517237. Epub 2013 Nov 4. Biomed Res Int. 2013. PMID: 24294611 Free PMC article. Review.
-
Regulation of ovarian cancer stem cells or tumor-initiating cells.Int J Mol Sci. 2013 Mar 25;14(4):6624-48. doi: 10.3390/ijms14046624. Int J Mol Sci. 2013. PMID: 23528891 Free PMC article. Review.
Cited by
-
Non-pharmaceutical interventions to optimize cancer immunotherapy.Oncoimmunology. 2023 Sep 28;12(1):2255459. doi: 10.1080/2162402X.2023.2255459. eCollection 2023. Oncoimmunology. 2023. PMID: 37791231 Free PMC article. Review.
-
Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches.Int J Mol Sci. 2023 Jun 26;24(13):10683. doi: 10.3390/ijms241310683. Int J Mol Sci. 2023. PMID: 37445860 Free PMC article. Review.
-
Reaction Behavior of [1,3-Diethyl-4,5-diphenyl-1H-imidazol-2-ylidene] Containing Gold(I/III) Complexes against Ingredients of the Cell Culture Medium and the Meaning on the Potential Use for Cancer Eradication Therapy.J Med Chem. 2023 Jun 22;66(12):8238-8250. doi: 10.1021/acs.jmedchem.3c00589. Epub 2023 Jun 9. J Med Chem. 2023. PMID: 37294951 Free PMC article.
-
Re-Sensitizing Cancer Stem Cells to Conventional Chemotherapy Agents.Int J Mol Sci. 2023 Jan 20;24(3):2122. doi: 10.3390/ijms24032122. Int J Mol Sci. 2023. PMID: 36768445 Free PMC article. Review.
-
Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects.J Immunother Cancer. 2022 Nov;10(11):e005401. doi: 10.1136/jitc-2022-005401. J Immunother Cancer. 2022. PMID: 36343977 Free PMC article. Review.
References
-
- Clevers H. The cancer stem cell: premises, promises and challenges. Nature medicine. 2011;17(3):313–319. - PubMed
-
- Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature reviews Cancer. 2008;8(10):755–768. - PubMed
-
- Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nature reviews Cancer. 2005;5(4):275–284. - PubMed
-
- Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell stem cell. 2007;1(3):313–323. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical